Drug Profile

VRS 808

Alternative Names: AMX-808; glucagon-XTEN; VRS-808

Latest Information Update: 08 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator
Developer Versartis
Class Antihypoglycaemics; Pancreatic hormones; Recombinant fusion proteins
Mechanism of Action Glucagon receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Hypoglycaemia

Most Recent Events

12 Jan 2024 Discontinued - Preclinical for Hypoglycaemia in USA (SC)
08 Feb 2022 Amunix has been acquired by Sanofi
15 Oct 2018 Versartis has merged with Aravive Biologics to form Aravive

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com